Clinical effect and safety of levosimendan, milrinone, and dobutamine in treatment of patients with ADHF
10.7501/j.issn.1674-6376.2017.01.017
- VernacularTitle:左西孟旦、米力农与多巴酚丁胺治疗急性失代偿心力衰竭患者临床疗效及安全性评价
- Author:
Lei WANG
- Keywords:
ADHF;
levosimendan;
milrinone;
dobutamine;
effect;
safety
- From:
Drug Evaluation Research
2017;40(1):92-95
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect and safety of levosimendan,milrinone,and dobutamine in treatment of patients with ADHF.Methods All 336 patients with ADHF accepted in Xi'an Center Hospital from April 2013 to April 2016 were selected and divided into group A,B,and C with 112 cases in each group.Patients in three groups were given levosimendan,milrinone,and dobutamine respectively.Then the clinical effect,hemodynamics,serum indexes,and safety of two groups were observed and compared.Results The total efficacy of group A (90.18％) was obviously higher than group B (58.93％) and group C (65.18％) with statistically significance (P ＜ 0.05).PCWP,PAMP,RAP,and SVR of three groups after treatment were lower than before (P ＜ 0.05).And PCWP,PAMP,and SVR of group A were obviously lower than those of group B and C (P ＜ 0.05).RAP among three groups after treatment had no difference.NT-proBNP,ET-1,and NE of three groups after treatment were lower than before (P ＜ 0.05),and group A was obviously lower than group B and C (P ＜ 0.05).Adverse reaction rate of group A was obviously lower than that of group B and C with statistically difference (P ＜ 0.05).Conclusion Levosimendan has better effect and safety than milrinone and dobutamine in treatment of patients with ADHF,which is worth clinical application.
